Suchergebnisse - "Fuchs, Ota"

PubPharm (22)

1

Targeting cereblon in hematologic malignancies

enthalten in: Blood reviews | 2023

von Fuchs, O.

2

Preclinical Studies of PROTACs in Hematological Malignancies

enthalten in: Cardiovascular & hematological disorders drug targets | 2021

von Fuchs, O. | Bokorova, R.

3

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes

enthalten in: Molecular oncology | 2020

von Pribyl, M. | Hubackova, S. | Moudra, A. | +10

4

Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs

enthalten in: Cardiovascular & hematological disorders drug targets | 2019

von Fuchs, O.

5

Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients)

enthalten in: Leukemia research | 2018

von Jonasova, A. | Neuwirtova, R. | Polackova, H. | +9

6

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin

enthalten in: PloS one | 2018

von Kuželová, K. | Brodská, B. | Schetelig, J. | +9

7

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

enthalten in: European journal of haematology | 2015

von Jonasova, A. | Bokorova, R. | Polak, J. | +12

8

Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia

enthalten in: PloS one | 2015

von Kuželová, K. | Brodská, B. | Fuchs, O. | +3

9

CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia

enthalten in: Journal of hematology & oncology | 2014

von Hájková, H. | Fritz, M. | Haškovec, C. | +11

10

Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma

enthalten in: Cardiovascular & hematological disorders drug targets | 2013

von Fuchs, O.